[Financial Highlights](index=1&type=section&id=Financial%20Highlights) This section summarizes Fulgent's financial performance for Q4 and full year 2023, highlighting revenue, profitability, and cash flow metrics [Fourth Quarter 2023 Results](index=1&type=section&id=Fourth%20Quarter%202023%20Results) In Q4 2023, Fulgent reported total revenue of $70.5 million, with Core Revenue growing 21% year-over-year to $66.5 million, alongside a significant GAAP loss due to goodwill impairment but positive non-GAAP income and cash from operations | Metric | Value | | :--- | :--- | | Total Revenue | $70.5 million | | Core Revenue | $66.5 million (+21% YoY) | | GAAP Loss | $128.1 million | | GAAP Loss per Share | $4.30 | | Non-GAAP Income | $8.3 million | | Non-GAAP Income per Share | $0.28 | | Adjusted EBITDA Loss | $6.8 million | | Cash from Operations | $14.9 million | - The company repurchased approximately **873,000 shares** of its common stock for **$22.9 million** during the quarter[7](index=7&type=chunk) [Full Year 2023 Results](index=1&type=section&id=Full%20Year%202023%20Results) For the full year 2023, total revenue was $289.2 million, with Core Revenue increasing 44% year-over-year to $262.1 million, resulting in a GAAP loss but positive Adjusted EBITDA and a strong cash position | Metric | Value | | :--- | :--- | | Total Revenue | $289.2 million | | Core Revenue | $262.1 million (+44% YoY) | | GAAP Loss | $167.8 million | | GAAP Loss per Share | $5.63 | | Non-GAAP Loss | $12.3 million | | Non-GAAP Loss per Share | $0.41 | | Adjusted EBITDA | $1.5 million | | Cash from Operations | $27.0 million | - The company ended 2023 with **$847.7 million** in cash, cash equivalents, and investments in marketable securities, which translates to approximately **$28 per share**[7](index=7&type=chunk)[9](index=9&type=chunk) - Throughout the year, Fulgent repurchased over **953,000 shares** of common stock at an aggregate cost of **$25.1 million**[11](index=11&type=chunk) [Management Commentary](index=2&type=section&id=Management%20Commentary) Management expressed satisfaction with 2023 performance, highlighting core business growth, therapeutic pipeline advancements, and a strong financial position [CEO and CFO Remarks](index=2&type=section&id=CEO%20and%20CFO%20Remarks) Management expressed satisfaction with the 2023 performance, highlighting the 44% year-over-year growth in the core business, driven by the Beacon787 Expanded Carrier screen, and progress in therapeutic development - CEO Ming Hsieh credited the **44% core business growth** in 2023 to the continued momentum in Precision Diagnostics, specifically the Beacon787 Expanded Carrier screen[8](index=8&type=chunk) - The therapeutic development pipeline is advancing, with the lead oncology drug FID-007 moving toward Phase 2 clinical testing and an Investigational New Drug (IND) application for FID-022 expected by the end of 2024[8](index=8&type=chunk) - CFO Paul Kim highlighted the company's **strong financial position** entering 2024, characterized by record core revenues, improving core gross margin, and a substantial cash balance[25](index=25&type=chunk) [Business Outlook](index=2&type=section&id=Business%20Outlook) This section provides Fulgent's financial guidance for the full year 2024, including projected core revenue, profitability, and year-end cash position [Full Year 2024 Guidance](index=2&type=section&id=Full%20Year%202024%20Guidance) For the full year 2024, Fulgent projects Core Revenue of approximately $280 million, anticipating a GAAP loss of around $2.25 per share and a non-GAAP loss of $1.05 per share, while maintaining a strong cash position | Metric | 2024 Guidance | | :--- | :--- | | Core Revenue | ~$280 million | | GAAP Loss per Share | ~$2.25 | | Non-GAAP Loss per Share | ~$1.05 | | Year-End Cash & Investments | ~$800 million | [Financial Statements](index=6&type=section&id=Financial%20Statements) This section presents Fulgent's condensed consolidated financial statements, including the balance sheet and statement of operations, for the reported periods [Condensed Consolidated Balance Sheet](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheet) As of December 31, 2023, Fulgent's balance sheet shows total assets of $1.24 billion, a decrease from 2022, but maintains a very strong liquidity position with $847.7 million in cash and marketable securities and robust stockholders' equity | Balance Sheet Item (in thousands) | Dec 31, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $97,473 | $79,506 | | Investments in marketable securities | $750,252 | $773,377 | | Total assets | $1,235,328 | $1,386,053 | | Total liabilities | $102,042 | $116,178 | | Total stockholders' equity | $1,133,286 | $1,269,875 | [Condensed Consolidated Statement of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations) The statement of operations for 2023 reflects a significant revenue decline due to reduced COVID-19 testing and a $120.2 million goodwill impairment charge, leading to a full-year net loss compared to prior year's net income | (in thousands) | Twelve Months 2023 | Twelve Months 2022 | | :--- | :--- | :--- | | Revenue | $289,213 | $618,968 | | Gross Profit | $104,456 | $366,901 | | Goodwill Impairment Loss | $120,234 | $0 | | Operating (Loss) Income | ($195,529) | $178,527 | | Net (Loss) Income Attributable to Fulgent | ($167,825) | $143,403 | | (in thousands, except per share data) | Q4 2023 | Q4 2022 | | :--- | :--- | :--- | | Revenue | $70,505 | $67,704 | | Operating Loss | ($151,121) | ($36,552) | | Net Loss Attributable to Fulgent | ($128,149) | ($23,832) | | Diluted Loss Per Share | ($4.30) | ($0.80) | [Reconciliation of GAAP to Non-GAAP Financial Measures](index=8&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) This section provides detailed reconciliations from GAAP to non-GAAP financial measures, including net income, EPS, and Adjusted EBITDA, to offer a clearer view of core operational performance [Reconciliation of Net (Loss) Income and EPS](index=8&type=section&id=Reconciliation%20of%20Net%20%28Loss%29%20Income%20and%20EPS) The reconciliation from GAAP to non-GAAP net income shows significant adjustments for non-cash and non-recurring items, converting a substantial GAAP loss into a much smaller non-GAAP loss for the full year 2023 and a non-GAAP income for Q4 2023 | Full Year 2023 Reconciliation (in thousands) | Amount | | :--- | :--- | | GAAP Net Loss | ($167,825) | | Goodwill Impairment Loss | +$120,234 | | Equity-based Compensation | +$42,922 | | Amortization of Intangibles | +$7,845 | | Non-GAAP Tax Effect | ($15,473) | | **Non-GAAP Net Loss** | **($12,297)** | | Per Share Data | Full Year 2023 | Full Year 2022 | | :--- | :--- | :--- | | GAAP Diluted (Loss) Income | ($5.63) | $4.63 | | Non-GAAP Diluted (Loss) Income | ($0.41) | $5.79 | [Reconciliation of Adjusted EBITDA](index=9&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) Adjusted EBITDA for the full year 2023 was $1.5 million, a significant decrease from 2022, calculated by adjusting GAAP net loss for interest, taxes, depreciation, amortization, goodwill impairment, and other non-cash charges | Adjusted EBITDA Reconciliation (in thousands) | Twelve Months 2023 | Twelve Months 2022 | | :--- | :--- | :--- | | Net (Loss) Income | ($167,825) | $143,403 | | Goodwill Impairment Loss | $120,234 | $0 | | Equity-based Compensation | $42,922 | $32,640 | | Depreciation and Amortization | $26,143 | $32,662 | | **Adjusted EBITDA** | **$1,504** | **$257,106** | [Non-GAAP Operating Margin](index=10&type=section&id=Non-GAAP%20Operating%20Margin) The company's GAAP gross margin declined significantly to 36.1% in 2023 from 59.3% in 2022, with non-GAAP gross margin also decreasing, leading to a substantial non-GAAP operating loss for 2023 | Margin Analysis | Twelve Months 2023 | Twelve Months 2022 | | :--- | :--- | :--- | | GAAP Gross Margin | 36.1% | 59.3% | | Non-GAAP Gross Margin | 39.5% | 60.7% | | Operating Profit (Loss) (in thousands) | Twelve Months 2023 | Twelve Months 2022 | | :--- | :--- | :--- | | GAAP Operating (Loss) Income | ($195,529) | $178,527 | | Non-GAAP Operating (Loss) Profit | ($24,528) | $228,573 | [Company Information and Disclosures](index=3&type=section&id=Company%20Information%20and%20Disclosures) This section provides an overview of Fulgent's business, outlines forward-looking statement disclaimers, and explains the use of non-GAAP financial measures [About Fulgent](index=3&type=section&id=About%20Fulgent) Fulgent Genetics is a technology-based company operating in laboratory services and therapeutic development, with a long-term strategic goal to evolve into a fully integrated precision medicine company - Fulgent operates two primary business segments: **laboratory services** and **therapeutic development**[27](index=27&type=chunk) - The company's strategic aim is to transform into a **fully integrated precision medicine company**[15](index=15&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section cautions investors that statements regarding future performance, guidance, clinical trial progress, and market opportunities are forward-looking and subject to numerous risks and uncertainties, which could cause actual results to differ materially - Forward-looking statements include guidance on financial results, the growth of testing services like the Beacon Expanded Carrier screen, and the expected timing and results of clinical trials[28](index=28&type=chunk) - Key risks highlighted include market adoption of tests, maintaining low costs and acceptable margins, volatility in results, customer concentration, and success in obtaining reimbursement from payors[17](index=17&type=chunk) [Note Regarding Non-GAAP Financial Measures](index=3&type=section&id=Note%20Regarding%20Non-GAAP%20Financial%20Measures) This note explains that non-GAAP financial measures are used to provide a clearer view of core operating results by excluding certain non-cash or non-recurring items, and should not be considered a substitute for GAAP measures - The company uses non-GAAP measures to provide a basis for measuring business performance, excluding items management believes are not directly tied to operating results[5](index=5&type=chunk) - Key adjustments to derive non-GAAP income from GAAP income include amortization of intangible assets, goodwill impairment loss, restructuring costs, acquisition-related costs, and equity-based compensation expenses[5](index=5&type=chunk)

Testing offers CBR families the opportunity to proactively seek additional information about their child's health TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive ne ...

Financial Data and Key Metrics - Total revenue for Q3 2023 was $85 million, down from $106 million in Q3 2022, with $19 million coming from COVID-19 testing, which was not part of the guidance [8] - Core revenue for Q3 2023 was $66 million, exceeding the guidance of $65 million and growing 17% year-over-year [8] - Gross margin was 47%, with the increase primarily related to COVID-19 revenues recognized on previously built tests due to successful insurance collection on appeals [8] - Adjusted EBITDA for Q3 2023 was $18.1 million, compared to $19.7 million in Q3 2022 [9] - Non-GAAP loss for the quarter was $11.7 million or $0.39 per share based on 30 million weighted average shares outstanding [9] - The company ended Q3 with approximately $851 million in cash, cash equivalents, and marketable securities, an increase of $4 million from Q2 [29] Business Line Data and Key Metrics - Precision Diagnostics revenue for Q3 2023 was $37.5 million, up 16% sequentially and 45% year-over-year [5] - Pharma Services revenue for Q3 2023 was $3.7 million, down 50% sequentially and up 19% year-over-year [5] - Beacon carrier screening portfolio continues to be a significant growth driver for Precision Diagnostics, with a mean turnaround time of 12 days [6] - The company updated its hereditary cancer panels to align with the latest NCCN guidelines, focusing on high to moderate risk factors for cancer [7] Market Data and Key Metrics - The company entered into a new agreement with Progyny for Beacon carrier screening, allowing it to provide reproductive genetic testing to the Progyny member network [25] - The company is focusing on gaining market share in the infertility space and planning for a rollout to the OB market [6] Company Strategy and Industry Competition - The company is moving forward with Phase II studies for FID-007 in head and neck cancer, with an initial study expected in Q1 2024 [4] - The company is being highly selective in evaluating M&A or strategic investment opportunities, focusing on organic growth and strengthening its market position [26] - The company expects ongoing integration efforts with recent acquisitions to create efficiencies and improve gross and operating margins in 2024 [10] Management Commentary on Operating Environment and Future Outlook - The company reiterated its core revenue guidance of $260 million for 2023, excluding additional revenues from COVID-19 testing [10] - Management is pleased with the trajectory and sees good momentum ahead, with a strong balance sheet and cash position [30] - The company expects to end the year with approximately $830 million of cash, cash equivalents, and investments, excluding stock repurchases since Q3 or other expenditures outside the ordinary course [30] Other Important Information - The company repurchased approximately 80,000 shares of common stock at an aggregate cost of $2.2 million in Q3, and an additional 533,000 shares at an aggregate cost of $13.7 million subsequent to the end of the quarter [29] - The company recognized a tax expense of $20 million in Q3 as it put up a reserve against deferred tax assets [28] Q&A Session Summary Question: Potential for additional COVID-19 collections - There is a chance for additional collections from COVID-19 in Q4 and beyond, but it is not something the company is counting on [34] Question: Seasonality and revenue guidance - Some seasonality is expected, especially in the Anatomic Pathology division, and the company is taking a conservative approach due to lumpiness in Pharma Services [40] Question: Anatomic Pathology (AP) business update - The AP business is stable but has seen a slight downtrend, partly due to seasonality and account-level profitability adjustments [41] Question: Fulgent Oncology expansion - The company has onboarded two new sales reps in different territories and is continuing to look for additional sales talent [43] Question: FDA LDT regulations impact - The company is monitoring FDA LDT regulations closely and is prepared to respond with its subject matter and operational expertise [48] Question: COVID reimbursement payments - The company has mostly exited COVID testing but continues to appeal claims and collect on accounts receivable from previous COVID testing [32] Question: Pharma Services lumpiness and macro environment - The company anticipates lumpiness in Pharma Services but expects over 100% increase in that business for 2023 compared to 2022 [36] Question: R&D spend for Phase II studies - The company expects an annual burn rate of around $50 million for new drug development efforts, including Phase II studies [57] Question: Beacon carrier screening and OB market - The company is seeing continued momentum in Beacon carrier screening and is planning for a rollout to the OB market [45] Question: Share gains in IVF setting - The company continues to see opportunities to gain share in the IVF setting as clients reassess their laboratory choices [64]

FORM 10-Q | --- | --- | --- | |-----------------------------------------------------------------------------------|-------------------|---------------------------------------------------| | Securities registered pursuant to Section 12(b) of the Act: \nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common Stock, par value $0.0001 per share | FLGT | The Nasdaq Stock Market (Nasdaq Global Market) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (M ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2023 Earnings Conference Call August 4, 2023 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Lawrence Weiss - Chief Medical Officer Conference Call Participants Dan Leonard - Credit Suisse David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Hello and welcome to the Fulgent Genetics Q2 2023 Earnings Conference Call ...

Cash used in investing activities in the six months ended June 30, 2023 was $5.5 million, which primarily related to $250.5 million on purchases of marketable securities and $14.2 million on purchases of fixed assets, including real estate, partially offset by $258.8 million related to maturities of marketable securities. Cash used in investing activities in the six months ended June 30, 2022 was $213.0 million, which primarily related to $245.5 million on purchase of marketable securities and $137.8 millio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4399 Santa Anita Avenue El Monte, CA 91731 (Address of principal executive offices) (Zip Code) (626) 350-0537 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | --- | --- | --- | |-------------------------------------------|-------------------|---- ...

Expansion and Acquisitions - The company opened a new CLIA-certified oncology laboratory in El Monte, California, expanding capabilities in somatic molecular diagnostics and cancer testing[476] - The acquisition of Inform Diagnostics extended the company's in-network relationships with managed care organizations to over 300 million covered lives[477] - The company's geographic footprint expanded with the addition of CLIA, CAP, and NY State certified laboratories in California, New York, Arizona, Massachusetts, and Texas[477] - The company completed the acquisition of Inform Diagnostics for approximately $170 million, expanding its genomic testing footprint into multiple pathology areas[536] - The company acquired businesses for $172.7 million in 2022, significantly higher than $61.9 million in 2021[494] - The company completed the acquisition of Inform Diagnostics and Fulgent Pharma in 2022 and is currently integrating them into operations[616] Financial Performance and Revenue - The company's revenue is impacted by the mix of tests delivered and customer concentration, with a small number of customers accounting for a significant portion of revenue in prior periods[481] - Revenue for the year ended December 31, 2022, was $659.4 million, a decrease from $1.14 billion in 2021[542] - Revenue for Q4 2022 was $67.704 million, a decrease from $105.655 million in Q3 2022 and $125.341 million in Q2 2022[563] - Gross profit for Q4 2022 was $12.987 million, significantly lower than $46.095 million in Q3 2022 and $65.276 million in Q2 2022[563] - Operating loss for Q4 2022 was $36.552 million, compared to an operating income of $201.933 million in Q1 2022[563] - Revenue from the Inform Diagnostics acquisition since the acquisition date was $83.6 million, with an operating loss of $17.0 million[553] - Revenue is primarily generated from testing services, with payments received from insurance, institutional customers, and direct patient payments[574] Profitability and Net Income - The company reported a net income of $507.36 million in 2021, contributing to a total equity of $1.27 billion at the end of 2022[490] - Net income from consolidated operations in 2022 was $141.9 million, a significant decrease from $506.2 million in 2021 and $214.3 million in 2020[494] - Net income attributable to Fulgent for 2022 was $140.3 million, compared to $493.3 million in 2021[542] Cash Flow and Investments - Net cash provided by operating activities in 2022 was $253.5 million, compared to $538.6 million in 2021 and $140.6 million in 2020[494] - Cash and cash equivalents at the end of 2022 were $79.5 million, down from $164.9 million at the end of 2021 and $87.4 million at the end of 2020[494] - The company invested $417.9 million in marketable securities in 2022, compared to $710.5 million in 2021 and $324.4 million in 2020[494] - Cash used in investing activities in 2022 was $261.3 million, primarily due to $418.0 million in purchases of marketable securities and $172.7 million related to business acquisitions[568] - Cash used in financing activities in 2022 was $77.1 million, mainly due to $74.3 million used in the repurchase of common stock[569] - Cash provided by operating activities in 2021 was $538.6 million, with adjustments including $15.9 million in equity-based compensation expenses and $11.0 million in depreciation and amortization[567] - Cash used in investing activities in 2021 was $546.5 million, including $710.5 million in purchases of marketable securities and $61.9 million related to business acquisitions[580] - Cash provided by financing activities in 2021 was $85.4 million, primarily from $89.5 million proceeds from an equity distribution agreement[581] Equity and Compensation - The company's equity-based compensation and stock issuances contributed significantly to its equity growth, with $32.64 million in equity-based compensation in 2021[490] - Equity-based compensation increased to $32.6 million in 2022 from $15.9 million in 2021 and $8.2 million in 2020[494] - The company's RSU (Restricted Stock Units) balance increased from 1,619 thousand shares in 2021 to 2,631 thousand shares in 2022, with a weighted-average grant date fair value of $47.76[520] - The company's option awards balance decreased from 216 thousand shares in 2021 to 212 thousand shares in 2022, with a weighted-average exercise price of $4.21[518] Tax and Financial Reporting - The company's effective tax rate decreased from 25.76% in 2021 to 22.70% in 2022, influenced by state taxes, uncertain tax positions, and stock-based compensation[525] - The company's deferred tax assets increased significantly from $21,920 thousand in 2021 to $56,587 thousand in 2022, primarily due to provisions for credit losses and net operating losses[526] - The company has $9.7 million of gross unrecognized tax benefits as of December 31, 2022, with $2.3 million potentially affecting the effective tax rate if recognized[529] - Management concluded that internal control over financial reporting was effective as of December 31, 2022[617] - The company's internal control over financial reporting was audited by Deloitte & Touche LLP, which expressed an unqualified opinion[618] Goodwill and Intangible Assets - The company's goodwill is subject to annual impairment tests, with impairment recognized if the fair value of the reporting unit is less than its carrying value[514] - The company's total goodwill as of December 31, 2022, was $143.0 million, up from $50.9 million in 2021[547] - Total intangible assets, net, increased to $150.643 million in 2022 from $35.914 million in 2021, driven by goodwill and customer relationships[560] - The company's intangible assets are amortized over periods ranging from five to fourteen years, with in-process research and development costs considered indefinite-lived until completion or abandonment[512] Stock Repurchase and Financing - The company repurchased $74.3 million of common stock in 2022, a new activity not present in previous years[494] - The company repurchased 1.8 million shares of its common stock at an aggregate cost of $74.3 million under the stock repurchase program in 2022, with $175.7 million remaining available for future repurchases[559][570] - A $250.0 million stock repurchase program was authorized in March 2022, with no expiration date[582] Risk Management and Liabilities - The company's allowance for credit losses increased from $11,217 thousand at the beginning of the year to $41,205 thousand at the end of the year, with a current period provision of $32,596 thousand[508] - The company holds a redeemable preferred stock investment valued at $12.4 million as of December 31, 2022, with unrealized losses of $9.6 million reported in other comprehensive income for the year[509] - A hypothetical 100 basis point increase in interest rates would result in a $7.3 million decline in the fair market value of the investment portfolio[591] - An adverse 10% foreign currency exchange rate change would decrease income before taxes by approximately $844,000 as of December 31, 2022[592] - As of December 31, 2022, the company had an outstanding balance of $15.0 million under its margin account and $5.2 million in notes payable due in March 2023[583] Therapeutic Development and Precision Medicine - The company's therapeutic development business focuses on improving the therapeutic window and pharmacokinetic profile of cancer drugs using a novel nanoencapsulation and targeted therapy platform[475] - The company's therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform[498] - The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company[498] - Fulgent Pharma's acquisition included $64.6 million in IPR&D, with a lead drug candidate, FID-007, showing promise in preliminary human clinical trials[543] Operational Costs and Expenses - The company incurred $1.2 million in costs related to COVID-19 antigen rapid test kits and licensing services in 2022[535] - The company's fixed assets are recorded at cost, net of accumulated depreciation, with major replacements and improvements capitalized and general repairs expensed as incurred[511] - The company has non-cancelable operating leases, finance leases, and purchase obligations for medical lab equipment, reagents, and other supplies as of December 31, 2022[572] Marketable Securities and Investments - The company uses the Black-Scholes option-pricing model to measure the fair value of option awards, requiring significant judgment in assumptions such as expected term[521] - The company's cash and cash equivalents are held in accounts at financial institutions, with amounts potentially exceeding federally insured limits, but management believes the credit risk is not significant[565] - Cash and cash equivalents as of December 31, 2022 include $5.0 million restricted cash related to a share transfer agreement[502]

ifulgent Investor Presentation November 7, 2022 Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Disclaimer 2 Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, among oth ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Paul Kim - CFO Brandon Perthuis - Chief Commercial Officer Dr. Ray Yin - President and Chief Scientific Officer, Fulgent Pharma Conference Call Participants Dan Leonard - Credit Suisse Operator Hello and welcome to the Fulgent Genetics Q3 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a ...